VISEN Pharmaceuticals
VISEN Pharmaceuticals

VISEN Pharmaceuticals

VISEN Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases.

Website
2017ActiveSan Diego, United States

About

VISEN Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for patients suffering from inflammatory and fibrotic diseases. Their lead drug candidate, VISN-101, is a novel small molecule inhibitor targeting a key pathway implicated in these conditions. The company aims to address significant unmet medical needs in areas like idiopathic pulmonary fibrosis (IPF) and other fibrotic disorders.

Key facts

At-a-glance profile data

Website
visenpharma.com
Headquarters
San Diego, United States
Founded
2017
Total funding
$200M
Business model
B2B
Tags
Biotech
Drug Discovery
Clinical Trials
Fibrotic Diseases
Inflammatory Diseases

Funding rounds

Funding rounds raised by VISEN Pharmaceuticals
DateRoundAmountLead investors
11 Jun 2025Undisclosed roundUndisclosedReynold Lemkins
1 Jan 2023Series B$50MDeerfield Management
8 Jan 2021Series B$150M-

Tech stack

Detected on visenpharma.com, last scanned 22 Sept 2026. Run your own scan

Frontend
Nuxt, jQuery, Bootstrap
Email provider
Self-hosted
Add first review

Frequently asked

How much funding has VISEN Pharmaceuticals raised?

VISEN Pharmaceuticals has raised a total of $200M in funding.